恒瑞医药：子公司收到HRS-1893片药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine's subsidiary received approval for clinical trials of HRS-1893, a drug aimed at treating heart failure with preserved ejection fraction, marking a significant development as no similar drugs have been approved in the market yet [1] Group 1 - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has been granted a clinical trial approval notice by the National Medical Products Administration for HRS-1893 [1] - The drug HRS-1893 is intended for the treatment of heart failure with preserved ejection fraction, a condition for which there are currently no approved similar drugs available domestically or internationally [1] - The total research and development investment for the HRS-1893 project has reached approximately 60.67 million yuan [1]